Dynamics of the Immune Response in Hospitalized SARS-CoV-2-infected Cancer Patients

Seroconversion rates were compared between oncological and nononcological patients infected with SARS-CoV-2 during a 14-day hospitalization time. All COVID-19 non-oncological and solid malignancies patients reached 100% seroconversion at day 14, while less than half of the hematological patients wer...

Full description

Saved in:
Bibliographic Details
Published in:Cancer investigation 2022-10, Vol.40 (9), p.750-759
Main Authors: Aoki, Mateus Nóbrega, Nardin, Jeanine Marie, Huergo, Luciano Fernandes, Blanes, Lucas, Morales, Hugo Manuel Paz, Fornazari, Bruna, Conzentino, Marcelo Santos, Migliorini, Maria Eduarda Alencar, Zanette, Dalila Lucíola
Format: Article
Language:English
Subjects:
cancer
COVID-19
IgG antibodies
immunity
seroconversion
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Seroconversion rates were compared between oncological and nononcological patients infected with SARS-CoV-2 during a 14-day hospitalization time. All COVID-19 non-oncological and solid malignancies patients reached 100% seroconversion at day 14, while less than half of the hematological patients were seroconverted at the same time point. Despite the limited number and variability of the patient's cohort, we conclude that there is a delayed seroconversion in the hematological malignancies group, which may be linked to changes in the hematological parameters, immune suppression and/or oncological treatments that are typically associated with these patients.
ISSN:0735-7907
1532-4192
DOI:10.1080/07357907.2022.2112693